JP2023541464A - ２－アミノ－３－カルボニルイミダゾピリジン及びピラゾロピリジン化合物 - Google Patents

２－アミノ－３－カルボニルイミダゾピリジン及びピラゾロピリジン化合物 Download PDF

Info

Publication number
JP2023541464A
JP2023541464A JP2023517408A JP2023517408A JP2023541464A JP 2023541464 A JP2023541464 A JP 2023541464A JP 2023517408 A JP2023517408 A JP 2023517408A JP 2023517408 A JP2023517408 A JP 2023517408A JP 2023541464 A JP2023541464 A JP 2023541464A
Authority
JP
Japan
Prior art keywords
pyridin
amino
imidazo
methanone
fluorocyclopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023517408A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541464A5 (https=
Inventor
リ，ジンファ
チョ，スヨン
リム，キョンスン
パク，アヨン
チャンデフ ゴーラクシュナート，ガデー
ナム，ファジュン
チョン，ヨングク
ファン，イェジン
キム，チェウン
キム，ミソン
ヤン，インヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
1St Biotherapeutics Inc
Original Assignee
1St Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1St Biotherapeutics Inc filed Critical 1St Biotherapeutics Inc
Publication of JP2023541464A publication Critical patent/JP2023541464A/ja
Publication of JP2023541464A5 publication Critical patent/JP2023541464A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2023517408A 2020-09-15 2021-09-14 ２－アミノ－３－カルボニルイミダゾピリジン及びピラゾロピリジン化合物 Pending JP2023541464A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063078372P 2020-09-15 2020-09-15
US63/078,372 2020-09-15
PCT/IB2021/058378 WO2022058890A1 (en) 2020-09-15 2021-09-14 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds

Publications (2)

Publication Number Publication Date
JP2023541464A true JP2023541464A (ja) 2023-10-02
JP2023541464A5 JP2023541464A5 (https=) 2024-02-07

Family

ID=80739409

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023517408A Pending JP2023541464A (ja) 2020-09-15 2021-09-14 ２－アミノ－３－カルボニルイミダゾピリジン及びピラゾロピリジン化合物

Country Status (7)

Country Link
US (1) US11744824B2 (https=)
EP (1) EP4214207A4 (https=)
JP (1) JP2023541464A (https=)
KR (1) KR20230067669A (https=)
AU (1) AU2021342777A1 (https=)
CA (1) CA3192158A1 (https=)
WO (1) WO2022058890A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024140970A1 (zh) * 2022-12-30 2024-07-04 广州市联瑞制药有限公司 双环类化合物及其制备方法和应用
WO2025103406A1 (zh) * 2023-11-15 2025-05-22 南京明德新药研发有限公司 6并5杂芳基衍生物及其应用
TW202525805A (zh) * 2023-12-29 2025-07-01 大陸商廣州市聯瑞製藥有限公司 雙環類化合物及其製備方法和應用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5154583A (en) * 1974-11-01 1976-05-13 Kyorin Seiyaku Kk Shinkipirazoro * 1 55a * pirijinjudotaino seizoho
JP2009530233A (ja) * 2006-02-14 2009-08-27 ノバルティス アーゲー Ｐｉ−３キナーゼインヒビターおよびそれらの使用方法
JP2009539851A (ja) * 2006-06-06 2009-11-19 アビジェン， インコーポレイテッド 置換ピラゾロ［１，５−ａ］ピリジン化合物およびその使用方法
WO2020056072A1 (en) * 2018-09-13 2020-03-19 Bristol-Myers Squibb Company 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4097483A (en) * 1974-11-01 1978-06-27 Kyorin Pharmaceutical Co., Ltd. Pyrazolo 1,5-a!pyridines
BRPI0610842A2 (pt) 2005-04-25 2010-07-27 Novartis Ag derivados de imidazo(1,2-a) piridina úteis como inibidores de peptìdeo desformilase (pdf)
JPWO2012102297A1 (ja) 2011-01-26 2014-06-30 杏林製薬株式会社 ピラゾロピリジン誘導体、またはその薬理学的に許容される塩
US20150158868A1 (en) 2013-12-06 2015-06-11 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN108084193A (zh) * 2017-12-19 2018-05-29 郭守东 一种brd4蛋白抑制剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5154583A (en) * 1974-11-01 1976-05-13 Kyorin Seiyaku Kk Shinkipirazoro * 1 55a * pirijinjudotaino seizoho
JP2009530233A (ja) * 2006-02-14 2009-08-27 ノバルティス アーゲー Ｐｉ−３キナーゼインヒビターおよびそれらの使用方法
JP2009539851A (ja) * 2006-06-06 2009-11-19 アビジェン， インコーポレイテッド 置換ピラゾロ［１，５−ａ］ピリジン化合物およびその使用方法
WO2020056072A1 (en) * 2018-09-13 2020-03-19 Bristol-Myers Squibb Company 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ARQUES, A. ET AL.: ""The Reaction of 1-Amino-4,6-diphenyl-2-methylthiopyridinium Iodide with Substituted Acetonitriles", SYNTHESIS, vol. 1981, no. 11, JPN7025000275, 1981, pages 910 - 912, ISSN: 0005707570 *
BELAROUSSI, R. ET AL.: ""Three successive and regiocontroled palladium cross-coupling reactions to easily synthesize novel", RSC ADVANCES, vol. 8, no. 2, JPN6025003378, 2018, pages 732 - 741, ISSN: 0005707574 *
HOU, JUE ET AL.: ""Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of in", CELL DEATH & DISEASE, vol. 10, no. 7, JPN6025003373, 2019, pages 1 - 13, ISSN: 0005707575 *
RAUF, ABDUL ET AL.: ""Synthesis, characterization, and urease inhibition of 5-substituted-8-methyl-2H-pyrido[1,2-a]pyrim", MEDICINAL CHEMISTRY RESEARCH, vol. 21, no. 1, JPN6025003376, 2012, pages 60 - 74, ISSN: 0005707573 *
REGISTRY（STN）[ONLINE], vol. Entered STN: 13 Feb 2014, JPN7025000276, pages 2024 - 12, ISSN: 0005707571 *
REGISTRY（STN）[ONLINE], vol. Entered STN: 19 Jul 2017, JPN7025000274, pages 2024 - 12, ISSN: 0005707569 *
SHESTAKOV, ALEXANDER S. ET AL.: ""Detailed Studies of the Alkylation Sides of Pyridin‐2‐yl and 4,6‐Dimethylpyrimidin‐2‐yl‐cyan", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 54, no. 1, JPN6025003374, 2017, pages 551 - 560, ISSN: 0005707572 *

Also Published As

Publication number Publication date
US11744824B2 (en) 2023-09-05
CA3192158A1 (en) 2022-03-24
AU2021342777A1 (en) 2023-04-27
CN116457355A (zh) 2023-07-18
KR20230067669A (ko) 2023-05-16
EP4214207A4 (en) 2024-10-02
AU2021342777A9 (en) 2024-05-30
WO2022058890A1 (en) 2022-03-24
EP4214207A1 (en) 2023-07-26
US20220087985A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
CN114867720B (zh) 杂芳基类衍生物及其制备方法和用途
CN113454082B (zh) 咪唑并吡啶基化合物及其用于治疗神经退行性疾病的用途
CN108349940B (zh) 布鲁顿酪氨酸激酶抑制剂
AU2006297948A1 (en) Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
WO2009027283A1 (en) Triazolopyridine compounds and their use as ask inhibitors
TW201446758A (zh) 作爲β－分泌酶抑制劑的全氟化５，６－二氫－４Ｈ－１，３－□－２－胺化合物及其用途
TW201710255A (zh) 雜環化合物
JP2023541464A (ja) ２－アミノ－３－カルボニルイミダゾピリジン及びピラゾロピリジン化合物
WO2017000276A1 (en) Bicyclic heterocyclic compounds as pde2 inhibitors
WO2016183741A1 (en) Pyrimidinone amide compounds as pde2 inhibitors
CN116457355B (zh) 2-氨基-3-羰基咪唑并吡啶和吡唑并吡啶化合物
US11926632B2 (en) Methods and compounds for restoring mutant p53 function
HK40096261A (zh) 2-氨基-3-羰基咪唑幷吡啶和吡唑幷吡啶化合物
EP4200299B1 (en) Compounds for prevention or treatment of neurodegenerative disorders
RU2833052C2 (ru) Имидазопиридинильные соединения и их применение для лечения нейродегенеративных расстройств
HK40058868A (en) Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders
HK40058868B (zh) 咪唑并吡啶基化合物及其用於治疗神经退行性疾病的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260114

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260421